US house subcommittee drops controversial language in FDA reform bills
This article was originally published in Clinica
Executive Summary
US House Democratic health leaders dropped a controversial proposal from draft Food and Drug Administration (FDA) reform bills this week that would have prohibited FDA law from pre-empting state court damage claims in an effort to move the package forward more quickly.